Aminoglycosides in early sepsis (AGES): A randomized pragmatic clinical trial comparing gentamicin and narrow spectrum betalactams to broad spectrum betalactams as empirical treatment in patients with suspected sepsis

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519797-39-00

Enrollment

2000

Registered

2025-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

Death up to 30 days after randomization, Any acute kidney injury up to 30 days after randomization

Detailed description

In-hospital mortality, Mortality up to 30 days after discharge, Duration of hospital stay, Duration of intensive care stay, Duration of ventilator therapy, Duration of vasopressor therapy, Hospital readmissions up to 30 days after discharge, Duration of antibiotic treatment

Interventions

DRUGPIPERACILLIN AND BETA-LACTAMASE INHIBITOR

DRUGBENZYLPENICILLIN

DRUGGENTAMICIN

DRUGCLOXACILLIN

DRUGCEFOTAXIME

DRUGAMPICILLIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Death up to 30 days after randomization, Any acute kidney injury up to 30 days after randomization	—

Secondary

Measure	Time frame
In-hospital mortality, Mortality up to 30 days after discharge, Duration of hospital stay, Duration of intensive care stay, Duration of ventilator therapy, Duration of vasopressor therapy, Hospital readmissions up to 30 days after discharge, Duration of antibiotic treatment	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026